Cue Biopharma, Inc.
CUEHealthcare|Biotechnology|US
$18.73
+0.72 (+4.00%)
Tangible Book / Share
$0.36
Cash / Share
$2.74
Clinical Trials (5)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT04852328 Three Schedules of CUE-101 Administered Before Surgery or Definitive Chemoradiation Therapy in HLA-A*0201 Positive Patients With Locally Advanced, HPV16-Positive Oropharyngeal Squamous-Cell Carcinoma | Oropharyngeal Squamous Cell Carcinoma | P2 | Recruiting | 30 | Open-label | CUE-101 |
| NCT07172256 CUE-101with Pembrolizumab for Locally Advanced HPV+HNSCCs | Head and Neck Squamous Cell Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma | P2 | Recruiting | 30 | RCT, Open-label | CUE-101, Pembrolizumab |
| NCT06917885 CUE-102 in Recurrent Glioblastoma | Recurrent Glioblastoma, Glioblastoma | P1 | Recruiting | 18 | Open-label | CUE-102 |
| NCT03978689 A Phase 1 Study in Patients With HPV16+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma | Head and Neck Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma | P1 | Completed | 80 | Open-label | CUE-101, KEYTRUDA®, Pembrolizumab |
| NCT05360680 A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers | Colorectal Cancer, Gastric Cancer | P1 | Completed | 42 | Open-label | CUE-102 |